3-fluoro-3-phenylpropanenitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-fluoro-3-phenylpropanenitrile
• 化学式: C₉H₈FN
• 分子量: 149.168
• InChiKey: HKCKOCROIBBUHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯代丙腈 在 iron(II) acetylacetonate 、 Selectfluor 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以44%的产率得到3-fluoro-3-phenylpropanenitrile
  参考文献：
  名称：

  金属催化的苯甲酸氟化物与氟化物的1,4-共轭加成反应的合成等价物

  摘要：

  我们详细探讨了铁催化的含芳环和吸电子基团彼此位于β彼此之间的基团的苄基氟化，从而提供了直接接触β氟化加合物的途径。可以认为这种操作上便利的方法不仅有助于及时解决苄基氟化问题，而且还可以等同于与氟化物的共轭加成反应等价的功能，从而以中等至良好的收率和优异的选择性提供了产品。

  DOI：

  10.1021/jo401796g

文献信息

• Substituted pyridine and pyridazine compounds and methods of use
  申请人：Amgen Inc.

  公开号：US06174901B1

  公开（公告）日：2001-01-16

  Selected novel substituted pyridine and pyridazine compounds are effective for prophylaxis and treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的小说替代吡啶和吡啶二氮化合物对于预防和治疗疾病，如TNF-α、IL-1β、IL-6和/或IL-8介导的疾病，以及其他疾病，如癌症、疼痛和糖尿病，具有有效性。该发明涵盖了新颖化合物、类似物、前药和其药学上可接受的盐，药物组合物以及用于预防和治疗涉及炎症、癌症、疼痛、糖尿病等疾病和其他疾病或病情的方法。该发明还涉及制备这类化合物的方法以及在这类方法中有用的中间体。
• Substituted indolizine-like compounds and methods of use
  申请人：——

  公开号：US20030195221A1

  公开（公告）日：2003-10-16

  Selected novel substituted indolizine-like compounds are effective for treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的类似吲哚啉的化合物对治疗疾病，如TNF-α、IL-1β、IL-6和/或IL-8介导的疾病，以及其他疾病，如癌症、疼痛和糖尿病具有有效性。本发明涵盖了新型化合物、类似物、前药和其药用可接受盐、制药组合物以及治疗涉及炎症、癌症、疼痛、糖尿病等疾病和其他疾患或情况的方法。该发明还涉及制备此类化合物的方法，以及在此类过程中有用的中间体。
• Metal-Catalyzed Benzylic Fluorination as a Synthetic Equivalent to 1,4-Conjugate Addition of Fluoride
  作者：Steven Bloom、Seth Andrew Sharber、Maxwell Gargiulo Holl、James Levi Knippel、Thomas Lectka

  DOI：10.1021/jo401796g

  日期：2013.11.1

  We explore in detail the iron-catalyzed benzylic fluorination of substrates containing aromatic rings and electron-withdrawing groups positioned β to one another, thus providing direct access to β-fluorinated adducts. This operationally convenient process can be thought of not only as a contribution to the timely problem of benzylic fluorination but also as a functional equivalent to a conjugate addition

  我们详细探讨了铁催化的含芳环和吸电子基团彼此位于β彼此之间的基团的苄基氟化，从而提供了直接接触β氟化加合物的途径。可以认为这种操作上便利的方法不仅有助于及时解决苄基氟化问题，而且还可以等同于与氟化物的共轭加成反应等价的功能，从而以中等至良好的收率和优异的选择性提供了产品。
• Silver-Catalyzed Radical Fluorination of Alkylboronates in Aqueous Solution
  作者：Zhaodong Li、Zhentao Wang、Lin Zhu、Xinqiang Tan、Chaozhong Li

  DOI：10.1021/ja509548z

  日期：2014.11.19

  We report herein an efficient and general method for the deboronofluorination of alkylboronates. Thus, with the catalysis of AgNO3, the reactions of various alkylboronic acids or their pinacol esters with Selectfluor reagent in acidic aqueous solution afforded the corresponding alkyl fluorides under mild conditions. A broad substrate scope and wide functional group compatibility were observed. A radical mechanism is proposed for this site-specific fluorination.
• FLORIN, C.;CHANTEGREL, J.;CHARLON, C.;MARSURA, A.;LUU-DUC, C., ANN. PHARM. FR., 1985, 43, N 6, 595-599
  作者：FLORIN, C.、CHANTEGREL, J.、CHARLON, C.、MARSURA, A.、LUU-DUC, C.

  DOI：——

  日期：——